TNFRSF8 and anaplastic large cell lymphoma: The same year, brentuximab vedotin was approved in combination with chemotherapy for adult patients with untreated systemic ALCL or another CD30-positive PTCL, based on the ECHELON-2 phase 3 trial (NCT01777152) [78, 79].